Por: The Boston Globe Business May 23, 2023
Regulators are to decide within days whether to clear a Cambridge biotech’s gene therapy for a deadly muscle-wasting disease that afflicts more than 10,000 boys and young men nationwide, even though questions remain about whether the treatment is safe and effective.The prospect that the Food and Drug Administration could give “accelerated approval” to the single-dose treatment from Sarepta Therapeutics . It has also drawn criticism from... + full article
The Boston Globe USA Business May 13, 2023
An panel of advisers Friday recommended that the Food and Drug Administration speed up approving a Duchenne muscular dystrophy treatment developed by Cambridge biotech Sarepta Therapeutics, despite questions about its clinical benefit and safety.By an 8 to 6 vote, the FDA... + más
Under pressure from patients, FDA faces tough choices on experimental gene therapy | The Boston Globe
FDA delays decision on Sarepta’s controversial gene therapy for muscular dystrophy | The Boston Globe
ABC News USA Life January 06, 2023
The 30 women who will compete for ' heart on The Bachelor season 27 have been revealed.The 26-year-old tech executive from Anaheim Hills, California, will meet a group that includes four nurses, along with a few other medical professionals, a nanny from Vienna, a dancer and... + más
When is The Bachelor Season 27 out? Release date, contestants plus more | Newsweek
All the stars on 'Bachelor in Paradise' cast and when you last saw them | Newsweek
Ars Technica USA Science January 05, 2023
Navigate Filter by topic Settings Front page layout Site theme - Jan 5, 2023 12:45 pm UTC MARK GARLICK/SCIENCE PHOTO LIBRARY Share this story Gene therapy has had a long and bumpy history. Although researchers have made some notable and Despite these issues, experts say there... + más
Opinion | The New York Times
First participant in test of custom gene editing therapy dies | The Boston Globe
ABC News USA Health November 23, 2022
WASHINGTON -- U.S. regulators on Tuesday approved the first gene therapy for hemophilia, a $3.5 million one-time treatment for the blood-clotting disorder.The Food and Drug Administration cleared Hemgenix, an IV treatment for adults with hemophilia B, the less common form of the... + más
FDA approves most expensive drug ever, $3.5 million-per-dose gene therapy for hemophilia B | CBS News
$3.5M gene therapy for hemophilia gets FDA approval | WPLG Local 10
WPLG Local 10 USA Health November 23, 2022
WASHINGTON – U.S. health regulators on Tuesday approved the first gene therapy for hemophilia, a $3.5 million one-time treatment for the blood-clotting disorder.The Food and Drug Administration cleared Hemgenix, an IV treatment for adults with hemophilia B, the less common... + más
$3.5M gene therapy for hemophilia gets FDA approval | ABC News
CBS News USA Health November 23, 2022
Washington — U.S. health regulators on Tuesday approved the first gene therapy for hemophilia, a $3.5 million one-time treatment for the blood-clotting disorder. The Food and Drug Administration cleared Hemgenix, an IV treatment for adults with hemophilia B, the less common... + más
Associated Press USA Science November 23, 2022
WASHINGTON (AP) — U.S. health regulators on Tuesday approved the first gene therapy for hemophilia, a $3.5 million one-time treatment for the blood-clotting disorder.The Food and Drug Administration cleared Hemgenix, an IV treatment for adults with hemophilia B, the less... + más
About iurex | Privacy Policy | Disclaimer |